Dizal Announces Clinical Results of Golidocitinib Published in Annals of Oncology
- Written by PR Newswire
![]() |
SHANGHAI, Sept. 10, 2023 /PRNewswire/ -- Dizal today announced the publication of the Phase I clinical data of golidocitinib for the treatment of relapsed or refractory (r/r) peripheral T cell lymphomas (PTCL) (JACKPOT8 PARTA) in Annals of Oncology (2022-2023 Impact Factor: 51.8).
PTCL is an aggressive non-Hodgkin lymphoma (NHL) that...
Read more: Dizal Announces Clinical Results of Golidocitinib Published in Annals of Oncology















